Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Sumitomo Pharma Co's share price for the quarter that ended in Dec. 2023 was $3.13. Sumitomo Pharma Co's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 397 Mil. Therefore, Sumitomo Pharma Co's market cap for the quarter that ended in Dec. 2023 was $1,244 Mil.
Sumitomo Pharma Co's quarterly market cap
declined
from Jun. 2023 ($1,736 Mil) to Sep. 2023 ($1,444 Mil) and
declined
from Sep. 2023 ($1,444 Mil) to Dec. 2023 ($1,244 Mil).
Sumitomo Pharma Co's annual market cap
declined
from Mar. 2021 ($7,449 Mil) to Mar. 2022 ($4,060 Mil) and
declined
from Mar. 2022 ($4,060 Mil) to Mar. 2023 ($2,533 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Sumitomo Pharma Co's Enterprise Value for Today is $3,418 Mil.
Sumitomo Pharma Co Market Cap Historical Data
The historical data trend for Sumitomo Pharma Co's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sumitomo Pharma Co's Market Cap
For the Drug Manufacturers - Specialty & Generic subindustry, Sumitomo Pharma Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sumitomo Pharma Co's Market Cap Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sumitomo Pharma Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Sumitomo Pharma Co's Market Cap falls into.
Sumitomo Pharma Co Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Sumitomo Pharma Co's Market Cap for the fiscal year that ended in Mar. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sumitomo Pharma Co (OTCPK:DNPUF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Sumitomo Pharma Co Market Cap Related Terms
Thank you for viewing the detailed overview of Sumitomo Pharma Co's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Sumitomo Pharma Co (Sumitomo Pharma Co) Business Description
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DNPUF has been successfully added to your 